Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926702 · ClinicalTrials.gov registry record · Early Phase 1
Tau Imaging With JNJ067
A Early Phase 1 study, sponsored by University of California, Berkeley.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT03926702: Completed Early Phase 1 study, sponsored by University of California, Berkeley.
NCT03926702 is a Early Phase 1 study that has completed, run by University of California, Berkeley. The registered enrollment target is 18 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03926702, a Early Phase 1 study, has completed, sponsored by University of California, Berkeley.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This protocol is designed to assess the utility of a new positron emission tomography (PET) radiopharmaceutical to image tau, \[18F\] JNJ067, invented by Janssen Pharmaceutical companies of Johnson \& Johnson. To date, the radiopharmaceutical has been used in a small group of patients and controls (\<20). The study plans to expand the range and number of subjects, to examine a total of 18 participants including controls and patients with Alzheimer's disease (AD) and other dementias. All patients will be recruited from the University of California, San Francisco (UCSF) Memory and Aging Center (MAC) and controls will be recruited from the University of California, Berkeley Aging Cohort Study (BACS). Patients will undergo a multidisciplinary clinical evaluation for diagnosis and a cognitive assessment at the MAC; controls will undergo the usual BACS cognitive assessment performed on the Berkeley campus. Following these evaluations UCSF subjects will undergo magnetic resonance imaging (MRI) scanning at the UCSF Neuroimaging Center and blood sampling for genetic testing also at UCSF, and BACS subjects will undergo an MRI at the University of California Berkeley 3T Brain Imaging Center (in Li Ka Shing hall on the Berkeley campus) and blood sampling for genetic testing at the time of the PET scan. All subjects will come to Lawrence Berkeley National Law (LBNL) where they will have, on the same day, a C-11 Pittsburgh compound B (PIB) PET scan to measure brain amyloid, and an F-18 JNJ067 PET scan to measure brain tau. These scans will be examined and analyzed by LBNL staff, and data will be processed to examine basic questions about the quantitative behavior of JNJ067. Scan results will not be returned to control subjects, but physicians at UCSF will receive scan results on MAC patients and will share results with participants. As part of this protocol, the investigators also plan to share the acquired data widely. All data will be de-identified. Data will be shared with t
Primary Outcome
PET standard uptake value ratio (SUVR) data
Interventions
- DRUG Radiopharmaceuticals
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-06-18 |
| Est. Completion | 2021-01-06 |
| Phase | Early Phase 1 |
What the finished NCT03926702 record still lists
NCT03926702 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 1 intervention - of which Radiopharmaceuticals is the first listed.
NCT03926702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03926702 about?
NCT03926702 is a clinical study titled "Tau Imaging With JNJ067". This protocol is designed to assess the utility of a new positron emission tomography (PET) radiopharmaceutical to image tau, \[18F\] JNJ067, invented by Janssen Pharmaceutical companies of Johnson \& Johnson. To date, the radiopharmaceutical has been used in a small group of patients and controls (...
What is the current status of trial NCT03926702?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2019-06-18. Estimated completion is 2021-01-06.
What interventions are being tested in trial NCT03926702?
The interventions under investigation include: Radiopharmaceuticals (DRUG).
Who is sponsoring clinical trial NCT03926702?
This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03926702's enrollment target sits among peer trials
18 1316th of 2000 higher than 651 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI